English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
最新的分析显示,65%的美国生物技术公司在寻找合适的合同研究机构(CRO)合作伙伴方面面临困难
Jan 16, 2024 19:00 HKT
最新的分析顯示,65%的美國生技公司在尋找合適的合約研究機構(CRO)合作夥伴方面面臨困難
Jan 16, 2024 19:00 HKT
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
Jan 12, 2024 16:00 HKT
冠科美博在中国完成复发或难治性急性髓细胞白血病uproleselan药物的三期临床桥接研究入组
Jan 03, 2024 20:10 HKT
冠科美博在中國完成復發或難治性急性髓細胞白血病uproleselan藥物的三期臨床橋接研究入組
Jan 03, 2024 20:09 HKT
아방스 클리니컬, 45개의 한국 생명 공학 기업 초청해 한국과 호주에서 미국으로 이어지는 글로벌레디 신약 개발 경로에 대한 설명회 개최
Oct 19, 2023 18:00 HKT
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
Oct 19, 2023 09:00 HKT
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
Aug 28, 2023 20:23 HKT
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
Aug 28, 2023 19:30 HKT
WholisticResearch Reveals the Best Nootropics of 2023
Aug 18, 2023 06:00 HKT
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics
Aug 17, 2023 21:00 HKT
亿胜生物公布2023年中期业绩 收入同比增长37.1% 净利润同比增长22.0%
Aug 16, 2023 19:08 HKT
億勝生物公佈2023年中期業績 收入同比增長37.1% 淨利潤同比增長22.0%
Aug 16, 2023 19:07 HKT
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Aug 16, 2023 19:06 HKT
亿胜生物宣布贝伐珠单抗眼科适应症I/II期临床研究成功完成
Jul 26, 2023 19:00 HKT
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成
Jul 26, 2023 18:59 HKT
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Jul 26, 2023 18:58 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 20:19 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 19:30 HKT
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Jul 20, 2023 16:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: